IDEA Collider: Innovation & Asymmetric Learning in Pharma

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today a tech pioneer, founder & CEO of Rapid Alpha joins us on the show as we discuss marketing intelligence & why business leaders can not ignore data quality.  Matthew talks about his career path from intellectual property to where he is now, about Rapid Alpha , what innovation management...

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today, Tim Kight,  a long-life student of elite performance, coach, and Focus 3 CEO joins us on the show as we discuss developing leaders & strengthening organizational culture to achieve better results. Tim delves into the five drivers of organizational greatness, training your team on beha...

Welcome to another amazing episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. In today’s episode, Mike is joined by John Waid. John is a thought leader, author, and CEO of a unique boutique global culture & leadership development firm. He talks about culture and the purpose of an organization. Additionally, he talks about the importance of knowing your; purpose, mission,...

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by a consultant, best-selling author, and one of the world’s top experts on strategy and innovation, Rita McGrath. In the episode, Rita talks to us about her transition from a political science career to innovation in the corporate venture, how to build an innovation prog...

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by Andrew Hopkins, the Founder & CEO  of Exscientia , as he talks to us about the use of AI in drug discovery.   In the episode, we delve into Andrew’s journey of developing better drug discovery methods, applying data mining in drug discovery, and the value of data integ...

In this incredible episode, Mike Rea is joined by Dr. John L. LaMattina. John is the former Senior Vice President of Pfizer Inc and President of Pfizer Global Research & Development. Additionally, he is a senior partner at PureTech Health and an author. He talks about the misconception about Pfizer’s profiteering from the pandemic and the drug pricing in America.  John also discusses how Gilead’s...

Welcome to another fantastic episode of the IDEA Collider│Asymmetric learning series with your host Mike Rea. Today we are joined by Gene Yoo, the Chief Executive Officer at Resecurity, Inc. He talks about asymmetric learning in cybersecurity & Intelligence and what gives Resecurity an edge over other competitors in the market Moreover, he shares about the signal validation process at Resecurity,...

Welcome to another fantastic episode of the IDEA Collider│Asymmetric learning series with your host Mike Rea. In today’s episode, Mike interviews Steven Johnson, an author of 13 books, a TV host, and a podcaster. He talks about Innovation vs. Invention and explains where good ideas come from.  Additionally, Steven talks about the Individual and organizational hunch collection tools and shares how...

Welcome to another fantastic episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by Billy Kenber, an investigative journalist at “The Times.” He talks about his journey to writing his book ‘Sick Money’ and the content in the book. Additionally, he talks about the pharmaceutical industry’s social contract with patients and how its distortion has led to...

Kabir Nath is President & CEO, Otsuka North America Pharmaceutical Business Throughout his career, Kabir has built bridges between cultures. His work has taken him across the globe, spanning 3 continents and multiple countries. Kabir has lived and worked in the United Kingdom, France, Spain, India, Singapore, China, and the United States. He has consistently inspired those around him to go beyond...

 (Now also released in paperback: https://amzn.to/3lWjo2B )  Kat can be found at First Create The Media :  and on Twitter: @Kat_Arney  Find out more about Rebel Cell here: https://www.rebelcellbook.com/about-rebel-cell-cancer-book Many of us think of cancer as a contemporary killer, a disease of our own making caused by our modern lifestyles. But, as Kat Arney explains in her new book REBEL CELL:...

As President of Novartis Oncology, Susanne Schaffert is pursuing a bold strategy to reimagine the research, development and commercialization of innovative treatments that will help improve and extend the lives of people with cancer and related blood disorders.  Susanne has held positions of increasing seniority across a range of business areas during her career at Novartis, having first joined th...

Dan Skovronsky is the chief scientific officer of Eli Lilly and Company. He serves as senior vice president of science and technology and president of Lilly Research Laboratories. He also has responsibility for global business development. Dan joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals Inc., where he had been CEO since founding the company in 2004. At Lilly, Dan has h...

With so much at stake in the application of AI/ Machine Learning to pharma, biotech and medicine, this wonderful book touches on biases, systems of learning, and the choices we have to make to properly harness the power of what is possible.  Email mike at ideapharma.com to enter a lottery to win a copy of the hardcover book, closing date 26th February. From the page at brianchristian.org: A jaw-dr...

  Syn is an award winning music agency and creative solutio, providing music strategy, composition, sound design and sonic branding for advertising, cinema and television, as well as music supervision, licensing and music curation services and our studios record voiceover, ADR and narration. In this interview, we discuss the user experience (patient, physician), via sound, for healthcare and pharm...

Great interview with Riccardo on CNBC Find out more about PTEN Research at https://www.ptenresearch.org

Covering a wide variety of topics, with a special focus on Novartis as one of the best examples of a learning organisation in pharma. On cultures of innovation, 'unbossing', decision making and measuring what matters John can be found on LinkedIn: https://www.linkedin.com/in/john-tsai-md-ab398b4/ or contacted by email at john_tsai.office at novartis.com

A discussion of The Playbook, from DiMe Society, Digital Clinical Measures  Introducing the essential industry guide for successfully developing & deploying digital clinical measures across clinical research, clinical care, and public health  https://playbook.dimesociety.org   More on Andy (Andrea) Coravos here: http://www.andreacoravos.com   More on Jen (Jennifer) Goldsack here: https://en.wikipe...

Carinne Brouillon is a Member of the Board of Managing Directors, with responsibility for the Human Pharma Business Unit  Professional milestones  2018 – 2019 Global Head of Therapeutic Areas, Boehringer Ingelheim  2014 – 2018 Head of Global Commercial Strategy Neuroscience at Janssen, Johnson & Johnson’s Pharmaceutical Company  2012 – 2018 President of Janssen Therapeutics and Member of the Janss...

This episode replays some of a round table we held at JP Morgan, back when people used to travel... It features the voices of Mike Rea, in conversation with Linda Avey, Co-founder of 23andMe, and Curious, Inc, Amrit Chaudhuri, CEO, Mass Innovation Labs (now SmartLabs), Steve Holtzman, then CEO, Decibel Therapeutics, Raj Kannan then SVP, Global Franchise Head, Neurology & Immunology, EMD Serono, Mi...

ABOUT THE INNOVATION DELUSION  Innovation is the hottest buzzword in business. But what if our obsession with finding the next big thing has distracted us from the work that matters most? “The most important book I’ve read in a long time . . . It explains so much about what is wrong with our technology, our economy, and the world, and gives a simple recipe for how to fix it: Focus on understanding...

Peter B. Bach is a physician, epidemiologist, researcher, and respected healthcare policy expert whose work focuses on the cost and value of anticancer drugs. Dr. Bach is leading efforts to increase understanding of the US drug development process and develop new models for drug pricing that include value to patients Dr. Bach described a 100-fold increase in cancer drug prices since 1965 after adj...

In conversation, discussing patient input into clinical programs, unmet need assessments, measurement and so much more. Jen was diagnosed with juvenile arthritis as an infant and now has a laundry list of other conditions and surprises (like a brain tumor). She is passionate about elevating and valuing the patient voice, and went on to become a health outcomes researcher, human factors engineer, F...

From the Amazon description : Pharmaceutical breakthroughs such as anti­biotics and vaccines rank among some of the greatest advancements in human history. Yet exorbitant prices for life-saving drugs, safety recalls affecting tens of millions of Americans, and soaring rates of addiction and overdose on pre­scription opioids have caused many to lose faith in drug companies. Now, Americans are deman...